Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 334,047
  • Shares Outstanding, K 57,298
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,660 K
  • EBIT $ -136 M
  • EBITDA $ -136 M
  • 60-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.62

Options Overview Details

View History
  • Implied Volatility 319.02% ( +109.99%)
  • Historical Volatility 102.24%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 319.02% on 01/02/25
  • IV Low 33.34% on 09/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 316
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 5,734
  • Open Int (30-Day) 4,639

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.63
  • Number of Estimates 5
  • High Estimate -0.53
  • Low Estimate -0.70
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.43 +2.49%
on 01/02/25
10.93 -49.13%
on 12/06/24
-4.65 (-45.54%)
since 12/02/24
3-Month
5.43 +2.49%
on 01/02/25
13.51 -58.85%
on 11/06/24
-6.49 (-53.86%)
since 10/02/24
52-Week
5.43 +2.49%
on 01/02/25
16.77 -66.86%
on 02/13/24
-8.17 (-59.50%)
since 01/02/24

Most Recent Stories

More News
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

OLMA : 5.53 (-5.15%)
Insider Sale: Director at $OLMA (OLMA) Sells 8,256 Shares

Cyrus Harmon, a director at $OLMA ($OLMA), sold 8,256 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.1% of their shares....

OLMA : 5.53 (-5.15%)
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

OLMA : 5.53 (-5.15%)
Olema Pharmaceuticals Announces FDA Clearance for OP-3136 IND Application, Phase 1 Clinical Trial Set to Begin in Early 2025

Olema Pharmaceuticals announces FDA clearance for Phase 1 trial of OP-3136, targeting breast cancer treatment.Quiver AI SummaryOlema Pharmaceuticals announced that the U.S. FDA has approved its Investigational...

OLMA : 5.53 (-5.15%)
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

OLMA : 5.53 (-5.15%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMA : 5.53 (-5.15%)
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

OLMA : 5.53 (-5.15%)
Olema Pharmaceuticals to Present New Data on Palazestrant (OP-1250) at San Antonio Breast Cancer Symposium 2024

Olema Pharmaceuticals will present Phase 1b/2 data on palazestrant with ribociclib at SABCS 2024.Quiver AI SummaryOlema Pharmaceuticals, Inc. announced that it will present new data from its Phase 1b/2...

OLMA : 5.53 (-5.15%)
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

OLMA : 5.53 (-5.15%)
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

OLMA : 5.53 (-5.15%)

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 6.41
2nd Resistance Point 6.20
1st Resistance Point 6.01
Last Price 5.53
1st Support Level 5.61
2nd Support Level 5.40
3rd Support Level 5.21

See More

52-Week High 16.77
Fibonacci 61.8% 12.44
Fibonacci 50% 11.10
Fibonacci 38.2% 9.76
Last Price 5.53
52-Week Low 5.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar